To include your compound in the COVID-19 Resource Center, submit it here.

Merck reports detailed data from Phase III KEYNOTE-040 trial of Keytruda in SCCHN

Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J.
Product: Keytruda pembrolizumab (MK-3475)
Business: Cancer
Molecular target: PD-1
Description: Humanized IgG4 mAb against PD-1
Indication: Treat recurrent or metastatic squamous cell carcinoma of the head

Read the full 284 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers